An Induction Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 1)

Open to people ages 18-80

• Diagnosis of UC for at least 3 months prior to baseline.
• Confirmed diagnosis of moderately or severely active UC, as assessed by the modified Mayo score (MMS).
• Demonstrated an inadequate response to, a loss of response to, or an intolerance to conventional or to biologic therapy for UC.
• If female, must meet the contraception requirements.

• Participants with a current diagnosis of Crohn's disease or inflammatory bowel disease-unclassified (indeterminate colitis).
• Participants with a previous colectomy.
• Participants with current evidence of toxic megacolon.
• Prior exposure to anti-IL12p40 antibodies (e.g. ustekinumab) or anti-IL-23p19 antibodies (e.g. risankizumab, brazikumab, guselkumab or tildrakizumab).